Risk of Interstitial Lung Disease in COVID-19 Patients with Autoimmune Diseases Treated with Antiviral Agents

Authors:

Xiangyang Huang M.D. Ph.D.[1]*, I-Han (Iressa) Cheng M.D.[2,3]*, Yu-Hsun Wang M.S.[2], Yao-min Hung MD, PhD.[4], James Cheng-Chung Wei M.D. Ph.D[2,5]
*Co-first authors

1. Department of Rheumatology and Immunology, West China School of Public Health and West China Fourth Hospital, Sichuan University, 610041, PR China
2. Chung Shan Medical University Hospital, Taichung, Taiwan
3. UCL Musculoskeletal Science and Medical Engineering, University College London, Stanmore, United Kingdom
4. Taipei Veterans General Taitung Branch, Taiwan.
5. Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan

Date: 08.09.24

Correspondence Author:

James Cheng-Chung Wei, MD, PhD.
Department of Allergy, Immunology & Rheumatology, Chung Shan Medical University Hospital, Taichung, Taiwan
Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan
Department of Nursing, Chung Shan Medical University, Taichung, Taiwan
Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan
No. 110, Sec. 1, Jianguo N. Rd., South District, Taichung City 40201, Taiwan
(TEL) + 886 4 24739595 #34718
E-mail: jccwei@gmail.com
ORCID 0000-0002-1235-0679

Yao-min Hung MD, PhD.
Department of Internal Medicine, Taipei Veterans General Taitung Branch, Taiwan.
No 1000, Gengsheng Rd, Taitung City, 95050, Taiwan, Division of Nephrology,
E-mail: ymhung1@gmail.com

Acknowledgements and Affiliation

Acknowledgements:

We thank the clinical and administrative staff at Chung Shan Medical University Hospital for their assistance with data collection and patient management, which made this study possible. Special thanks to the data analysis team for their support with the statistical evaluations. We also appreciate the contributions of all participants who consented to use their medical records for research.

This study did not receive any direct financial support from pharmaceutical companies. However, the resources for conducting this study were provided by the Chung Shan Medical University Hospital, Taichung, Taiwan.

Affiliations:

- **I-Han (Iressa) Cheng**
  Chung Shan Medical University Hospital, Taichung, Taiwan.
- **Xiangyang Huang M.D. Ph.D.**
  Department of Rheumatology and Immunology, West China School of Public Health and West China Fourth Hospital, Sichuan University, 610041, PR China.
- **Yu-Hsun Wang MS.**
  Chung Shan Medical University Hospital, Taichung, Taiwan.
- **James Cheng-Chung Wei M.D. Ph.D.**
  Vice Superintendent, Division of Allergy Immunology and Rheumatology, Clinical Trial Center, Chung Shan Medical University Hospital, Taichung, Taiwan.
- **Yao-min Hung M.D. PhD.**
  Department of Internal Medicine, Taipei Veterans General Taitung Branch, Taiwan.

Abstract

Background: The safety of Paxlovid and Molnupiravir in COVID-19 patients with autoimmune diseases remains unclear, particularly concerning the risk of interstitial lung disease (ILD).

Objective: To evaluate the risk of developing ILD among COVID-19 patients with autoimmune diseases treated with Paxlovid or Molnupiravir.

Design: Retrospective cohort study.

Setting: Data were Based on data from the US Collaborative Network in TriNetX

Patients: 18,384 COVID-19 patients with pre-existing autoimmune diseases.

Interventions: Treatment with Paxlovid or Molnupiravir within five days of COVID-19 diagnosis.

Measurements: ILD diagnosis confirmed by ICD-10-CM codes and radiographic evidence.

Results: ILD occurred in 54 patients in the Paxlovid group and 79 patients in the Molnupiravir group (HR: 0.73, 95% CI: 0.52–1.03), indicating no statistically significant difference. Subgroup analyses by age, sex, and race showed consistent results.

Limitations: Observational design limits causal inference; potential residual confounding.

Conclusion: Treatment with Paxlovid or Molnupiravir does not significantly increase ILD risk in COVID-19 patients with autoimmune diseases.

Primary Funding Source: Chung Shan Medical University Hospital.

Registration: Not applicable.

Key messages

What is already known on this topic:

- The safety of COVID-19 antiviral treatments, particularly **nirmatrelvir-ritonavir (Paxlovid)** and Molnupiravir, in patients with autoimmune diseases has been poorly understood. Patients with autoimmune conditions are considered high-risk due to compromised immune systems and potential susceptibility to complications like **interstitial lung disease (interstitial lung disease)**.
- Previous studies have generally excluded or underrepresented patients with autoimmune diseases, creating a significant knowledge gap regarding the safety of these treatments for this vulnerable population.

What this study adds:

- This study provides evidence that there is no statistically significant difference in the risk of developing **interstitial lung disease** between COVID-19 patients with autoimmune diseases treated with **nirmatrelvir-ritonavir** or Molnupiravir.
- It reinforces that both antiviral treatments can be used safely regarding the risk of **interstitial lung disease** in patients with pre-existing autoimmune conditions, addressing an important gap in the literature.

How this study might affect research, practice, or policy:

- The findings could influence clinical guidelines and policy decisions regarding the management of COVID-19 in patients with autoimmune diseases, suggesting that healthcare providers can use either **nirmatrelvir-ritonavir** or Molnupiravir without an increased risk of **interstitial lung disease**.
- This study might prompt further research into the long-term effects of COVID-19 treatments on different subpopulations, particularly those with chronic underlying conditions.

- Policymakers might consider these results when developing targeted recommendations for COVID-19 treatment in populations at increased risk for severe outcomes.

Introduction

In the fight against COVID-19, the advent of antiviral agents such as nirmatrelvir–ritonavir (Paxlovid) and Molnupiravir represents a significant development in outpatient SARS-CoV-2 management(1-3), complementing other treatments like monoclonal antibodies and remdesivir(4). These medications play a pivotal role in mitigating disease severity, particularly among high-risk populations. However, the safety and efficacy of these treatments in patients with pre-existing autoimmune diseases remain largely unknown, a group notably susceptible due to compromised immune systems(5, 6). This uncertainty highlights the crucial need to evaluate the safety profiles of COVID-19 treatments for individuals with autoimmune conditions, especially concerning the risk of interstitial lung disease—a severe condition characterized by lung tissue scarring.

Historically, clinical trials that demonstrated the effectiveness of these outpatient treatments predated the emergence of new viral variants and the widespread administration of COVID-19 vaccines(1-4). Moreover, these studies often underrepresented immunosuppressed individuals, such as those with systemic autoimmune rheumatic diseases, with very few such patients included in pivotal trials(1-4). This oversight is significant because studies have indicated that patients with conditions like rheumatoid arthritis are more susceptible to SARS-CoV-2 infection and severe outcomes from COVID-19(7-15). Yet, the impact of specific rheumatoid arthritis features like interstitial lung disease, serostatus, and bone erosions on COVID-19 outcomes remains poorly characterized(9, 14, 15). Furthermore, previous research has been limited by non-representative patient demographics and a lack of detailed clinical data, which could influence the management and risk assessments for these patients(7-15).

The current landscape underscores an urgent need for effective and safe COVID-19 treatments across diverse patient demographics, including those with autoimmune disorders(1-3) (4). Previous studies have shed light on the general pharmacodynamics and safety of nirmatrelvir-ritonavir and Molnupiravir, yet gaps remain regarding their use in autoimmune populations, particularly concerning interstitial lung disease risks. (16, 17)These gaps may obscure potential adverse effects, such as interstitial lung disease exacerbation, necessitating a focused investigation into how these antivirals interact with autoimmune pathology and immunosuppressive treatments.

Addressing these critical gaps, this study aims to rigorously assess whether the use of nirmatrelvir-ritonavir and Molnupiravir increases the risk of interstitial lung disease among patients with autoimmune diseases post-COVID-19 infection. Employing a retrospective cohort study design and utilizing propensity score matching, this research strives to provide a robust comparison between patient groups receiving each antiviral treatment. This approach will help mitigate confounding factors, offering clearer insights into the risk profiles of these drugs and aiding in the formulation of safer clinical strategies for this vulnerable patient cohort.

Methods

Study Design
We conducted a retrospective cohort study using data from the US Research Network, which includes a large sample of individuals diagnosed with COVID-19 between 2020 and 2023. To assess the comparative risk of interstitial lung disease (ILD) in COVID-19 patients with autoimmune diseases treated with nirmatrelvir-ritonavir (Paxlovid) and Molnupiravir, we applied 1:1 propensity score matching (PSM) to minimize confounding factors between the two groups. The primary outcome was the development of ILD after the administration of antiviral treatments.

Study Population
The study population consisted of 112,376,696 individuals diagnosed with COVID-19 (defined by laboratory-confirmed SARS-CoV-2 infection or ICD-10-CM code U07.1) from 2020 to 2023. Patients with a pre-existing diagnosis of ILD before or within 5 days of the initial COVID-19 diagnosis were excluded. The final matched cohort included 9,192 patients in each treatment group: those treated with nirmatrelvir-ritonavir and those treated with Molnupiravir.

Propensity Score Matching
To reduce confounding, we performed 1:1 PSM based on multiple covariates, including demographic factors (age, sex, race, and socioeconomic status), medical history (comorbidities such as hypertension, diabetes, and ischemic heart disease), and medications (e.g., immunosuppressants such as methotrexate and corticosteroids). Additional variables included vaccination status, baseline healthcare utilization, and the presence of diagnosed autoimmune diseases prior to the index date. These factors were selected based on their known association with COVID-19 outcomes and ILD risk.

Covariates
The key covariates included demographic factors, such as age, sex, race, and socioeconomic status (SES), medical history relevant to autoimmune diseases and COVID-19 severity, and the use of immunosuppressive medications like corticosteroids, methotrexate, and tocilizumab. We also accounted for the patients' comorbidities, such as hypertension, diabetes, and ischemic heart disease, as well as their COVID-19 vaccination status.

Outcomes
The primary outcome was the incidence of interstitial lung disease (ILD) post-treatment with either antiviral agent. ILD was defined by ICD-10-CM code J84 and confirmed by radiographic evidence.

Statistical Analysis
We used Kaplan-Meier survival analysis to compare the risk of ILD between the two treatment groups, with hazard ratios (HR) and 95% confidence intervals (CI) calculated using Cox proportional hazards models. Subgroup analyses were performed by age, sex, and race to further explore potential differences in treatment effects across these populations. A standardized mean difference (SMD) was used to assess the balance between the treatment groups after PSM.

Ethical Approval

This study was approved by the Institutional Review Board (IRB) of Chung Shan Medical University Hospital (IRB NO: CS2-21176).

Figure Legends



Figure 1. Flowchart of the study cohort selection and propensity score matching process.

This figure illustrates the selection process for the study cohort, including inclusion and exclusion criteria, and the PSM process used to balance baseline characteristics between the Paxlovid and Molnupiravir groups.

Results

Patient Demographics and Baseline Characteristics:
Our study initially included 81,944 patients, with each treatment group (nirmatrelvir-ritonavir and Molnupiravir) comprising 40,997 and 40,947 patients, respectively, prior to matching. After performing propensity score matching, each group was balanced with 9,192 patients. The matching criteria included age, sex, race, socioeconomic status, medical utilization, comorbidities, SARS-CoV-2 vaccination status, and diagnosed autoimmune diseases prior to the index date. The average age of the patients was 64.59 years (standard deviation: 15.19 years). Both groups were well-matched for other baseline characteristics, with no significant imbalances in terms of key demographic and clinical factors, as shown in Table 1.

Table 1 Demographic characteristics of Paxlovid and Molnupiravir

	Before PSM matching				After PSM matching			
	Paxlovid N = 40997	Molnupiravir N = 9252	p	SMD	Paxlovid N = 9192	Molnupiravir N = 9192	p	SMD
Age	59.27 ± 16.58	64.71 ± 15.26	0.000	0.341	64.52 ± 15.12	64.66 ± 15.26	0.551	0.009
Sex								
Female	25676 (62.63)	5680 (61.39)	0.027	0.025	5593 (60.85)	5652 (61.49)	0.372	0.013
Male	12189 (29.73)	3252 (35.15)	0.000	0.116	3279 (35.67)	3220 (35.03)	0.363	0.013
Race								
White	31337 (76.44)	7695 (83.17)	0.000	0.168	7701 (83.78)	7643 (83.15)	0.250	0.017
Black or African American	2344 (5.72)	661 (7.14)	0.000	0.058	636 (6.92)	653 (7.10)	0.623	0.007
Asian	1212 (2.96)	199 (2.15)	0.000	0.051	190 (2.07)	199 (2.17)	0.645	0.007
BMI								
<30	8630 (21.05)	2737 (29.58)	0.000	0.197	2690 (29.27)	2702 (29.40)	0.846	0.003
≥30	6291 (15.35)	2529 (27.34)	0.000	0.296	2428 (26.41)	2485 (27.03)	0.342	0.014
Mean ± SD	29.53 ± 6.81	30.52 ± 6.91	0.000	0.144	30.18 ± 6.71	30.52 ± 6.92	0.018	0.049
Medical utilization								
Ambulatory	39596 (96.58)	9042 (97.73)	0.000	0.069	8940 (97.26)	8983 (97.73)	0.043	0.030
Emergency	9452 (23.06)	2585 (27.94)	0.000	0.112	2596 (28.24)	2551 (27.75)	0.460	0.011
Inpatient Encounter	4234 (10.33)	1667 (18.02)	0.000	0.222	1560 (16.97)	1628 (17.71)	0.185	0.020
Comorbidities								

Hypertensive diseases	18796 (45.85)	5930 (64.09)	0.000	0.373	5888 (64.06)	5870 (63.86)	0.782	0.004
Diabetes mellitus	9782 (23.86)	3210 (34.70)	0.000	0.240	3096 (33.68)	3156 (34.33)	0.350	0.014
Ischemic heart diseases	4766 (11.63)	2140 (23.13)	0.000	0.307	2047 (22.27)	2085 (22.68)	0.502	0.010
Noninfective enteritis and colitis	5722 (13.96)	1286 (13.90)	0.885	0.002	1208 (13.14)	1278 (13.90)	0.131	0.022
Persons with potential health hazards related to socioeconomic and psychosocial circumstances	2320 (5.66)	1229 (13.28)	0.000	0.263	1150 (12.51)	1178 (12.82)	0.535	0.009
Tobacco use	2215 (5.40)	1126 (12.17)	0.000	0.241	1039 (11.30)	1081 (11.76)	0.332	0.014
Nicotine dependence	2905 (7.09)	994 (10.74)	0.000	0.129	964 (10.49)	966 (10.51)	0.962	0.001
Problems related to housing and economic circumstances	1345 (3.28)	897 (9.70)	0.000	0.263	824 (8.96)	852 (9.27)	0.473	0.011
Other rheumatoid arthritis	2341 (5.71)	555 (6.00)	0.282	0.012	530 (5.77)	550 (5.98)	0.530	0.009
Type 1 diabetes mellitus	2097 (5.12)	488 (5.28)	0.530	0.007	465 (5.06)	483 (5.26)	0.548	0.009
Psoriasis	2666 (6.50)	484 (5.23)	0.000	0.054	461 (5.02)	482 (5.24)	0.483	0.010
Other necrotizing vasculopathies	770 (1.88)	368 (3.98)	0.000	0.125	344 (3.74)	350 (3.81)	0.816	0.003
Alcohol related disorders	1065 (2.60)	328 (3.55)	0.000	0.055	339 (3.69)	325 (3.54)	0.580	0.008
Sjögren syndrome	1228 (3.00)	252 (2.72)	0.163	0.016	229 (2.49)	252 (2.74)	0.288	0.016
Myositis	613 (1.50)	251 (2.71)	0.000	0.085	222 (2.42)	245 (2.67)	0.281	0.016
Rheumatoid arthritis with rheumatoid factor	1071 (2.61)	200 (2.16)	0.013	0.030	184 (2.00)	199 (2.17)	0.439	0.011
Autoimmune thyroiditis	1974 (4.82)	215 (2.32)	0.000	0.135	180 (1.96)	215 (2.34)	0.075	0.026
Systemic lupus erythematosus	695 (1.70)	177 (1.91)	0.147	0.016	175 (1.90)	174 (1.89)	0.957	0.001
Polymyalgia rheumatica	591 (1.44)	162 (1.75)	0.027	0.025	133 (1.45)	162 (1.76)	0.089	0.025
Atopic dermatitis	953 (2.33)	129 (1.39)	0.000	0.069	116 (1.26)	129 (1.40)	0.403	0.012

Problems related to employment and unemployment	230 (0.56)	96 (1.04)	0.000	0.054	97 (1.06)	94 (1.02)	0.827	0.003
Celiac disease	556 (1.36)	95 (1.03)	0.011	0.030	70 (0.76)	95 (1.03)	0.051	0.029
Vasculitis limited to skin, not elsewhere classified	175 (0.43)	51 (0.55)	0.106	0.018	53 (0.58)	50 (0.54)	0.767	0.004
Autoimmune hepatitis	123 (0.30)	45 (0.49)	0.005	0.030	45 (0.49)	43 (0.47)	0.831	0.003
Ankylosing spondylitis	290 (0.71)	49 (0.53)	0.059	0.023	42 (0.46)	49 (0.53)	0.462	0.011
Other overlap syndromes	97 (0.24)	31 (0.34)	0.090	0.018	34 (0.37)	30 (0.33)	0.616	0.007
Systemic sclerosis [scleroderma]	117 (0.29)	27 (0.29)	0.917	0.001	30 (0.33)	27 (0.29)	0.691	0.006
Dermatopolymyositis	76 (0.19)	19 (0.21)	0.689	0.005	17 (0.19)	18 (0.20)	0.866	0.002
Behçet's disease	33 (0.08)	10 (0.11)	0.412	0.009	10 (0.11)	10 (0.11)	1.000	0.000
Polyarteritis nodosa and related conditions	25 (0.06)	14 (0.15)	0.005	0.028	10 (0.11)	14 (0.15)	0.414	0.012
Medications								
Methotrexate	961 (2.34)	196 (2.12)	0.191	0.015	175 (1.90)	194 (2.11)	0.318	0.015
Cyclosporine	440 (1.07)	113 (1.22)	0.217	0.014	106 (1.15)	111 (1.21)	0.733	0.005
Cyclophosphamide	71 (0.17)	19 (0.21)	0.509	0.007	22 (0.24)	18 (0.20)	0.527	0.009
Zidovudine	10 (0.02)	0 (0.00)	0.133	0.022	0 (0.00)	0 (0.00)	0.000	0.000
Baricitinib	10 (0.02)	10 (0.11)	0.000	0.033	10 (0.11)	10 (0.11)	1.000	0.000
Tocilizumab	65 (0.16)	25 (0.27)	0.022	0.024	21 (0.23)	25 (0.27)	0.555	0.009
Corticosteroids for systemic use	18104 (44.16)	4713 (50.94)	0.000	0.136	4572 (49.74)	4667 (50.77)	0.161	0.021
SARS-CoV-2 (COVID-19) Vaccine	7168 (17.48)	1092 (11.80)	0.000	0.161	1029 (11.20)	1090 (11.86)	0.159	0.021
mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, for intramuscular use	1760 (4.29)	268 (2.90)	0.000	0.075	237 (2.58)	268 (2.92)	0.162	0.021

mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	916 (2.23)	153 (1.65)	0.000	0.042	135 (1.47)	151 (1.64)	0.340	0.014
mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage, for intramuscular use	320 (0.78)	58 (0.63)	0.122	0.018	50 (0.54)	57 (0.62)	0.497	0.010
mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use	653 (1.59)	101 (1.09)	0.000	0.044	95 (1.03)	100 (1.09)	0.719	0.005
SARS-CoV-2 (COVID-19) Vaccine	7168 (17.48)	1092 (11.80)	0.000	0.161	1029 (11.20)	1090 (11.86)	0.159	0.021
Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD)	79.27 ± 21.57	70.47 ± 23.91	0.000	0.387	75.59 ± 21.36	70.53 ± 23.88	0.000	0.224
Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD)	29381 (71.67)	7132 (77.09)	0.000	0.387	7024 (76.41)	7078 (77.00)	0.000	0.224
Cholesterol in HDL [Mass/volume] in Serum or Plasma	53.58 ± 20.10	52.77 ± 18.05	0.005	0.042	52.48 ± 18.85	52.80 ± 18.02	0.362	0.017
Cholesterol in HDL [Mass/volume] in Serum or Plasma	23034 (56.19)	5759 (62.25)	0.005	0.042	5707 (62.09)	5711 (62.13)	0.362	0.017
Cholesterol in LDL [Mass/volume] in Serum or Plasma	100.52 ± 36.33	91.69 ± 36.50	0.000	0.243	95.42 ± 36.96	91.73 ± 36.47	0.000	0.101
Cholesterol in LDL [Mass/volume] in Serum or Plasma	22912 (55.89)	5752 (62.17)	0.000	0.243	5690 (61.90)	5705 (62.07)	0.000	0.101
Hemoglobin A1c/Hemoglobin.total in Blood	6.25 ± 1.39	6.37 ± 1.45	0.000	0.086	6.37 ± 1.35	6.37 ± 1.45	0.839	0.004
Hemoglobin A1c/Hemoglobin.total in Blood	18216 (44.43)	4717 (50.98)	0.000	0.086	4550 (49.50)	4674 (50.85)	0.839	0.004

SMD: standardized mean difference.

If the patient's count is 1–10 or less, the results indicate a count of 10.

Primary Outcome:
The primary outcome measured was the incidence of interstitial lung disease (ILD). In the nirmatrelvir-ritonavir group, ILD was reported in 54 out of 9,192 patients, while in the Molnupiravir group, it was observed in 79 out of 9,192 patients. This resulted in a hazard ratio (HR) of 0.73 (95% CI: 0.52–1.03), indicating no statistically significant difference in the risk of ILD between the two treatment groups, as the confidence interval includes 1. These results are detailed in Table 2 and illustrated in Figure 2. The findings suggest that the use of either antiviral treatment does not increase the risk of ILD among COVID-19 patients with autoimmune diseases.

Table 2. Risk of outcomes exposed to Paxlovid compared to Molnupiravir

	No. of event		
	Paxlovid N = 9192	Molnupiravir N = 9192	HR (95% C.I.)
All durations	54	79	0.73 (0.52–1.03)



Figure 2 Kaplan-Meier analysis for risk of interstitial lung disease

Secondary Outcomes: Secondary outcomes included medical utilization patterns post COVID-19 diagnosis. Analysis revealed no significant differences in the utilization of ambulatory, emergency, and inpatient healthcare services between the two groups.

Subgroup Analysis: Subgroup analysis was conducted to evaluate the risk of interstitial lung disease (ILD) based on age, sex, and race. The hazard ratio (HR) for patients under 65 was 0.97 (95% CI: 0.55–1.73), and for those aged 65 and above was 1.03 (95% CI: 0.70–1.50). Regarding sex, the HR was 1.10 (95% CI: 0.74–1.64) for females and 0.81 (95% CI: 0.45–1.45) for males. Racial analysis showed an HR of 0.92 (95% CI: 0.65–1.30) for White patients and 3.74 (95% CI: 0.74–18.84) for Black or African American patients, indicating a wide confidence interval due to low event numbers. These findings are summarized in Table 3 and visualized in the Forest plot (Figure 3).

Table 3 Stratification of risk of interstitial lung disease exposed to Paxlovid compared to Molnupiravir

	Paxlovid		Molnupiravir		
	N	No. of ILD	N	No. of ILD	HR (95% C.I.)
Age					
<65	4054	22	4054	25	0.97 (0.55-1.73)
≥65	4882	52	4882	54	1.03 (0.70-1.50)
Sex					
Female	5662	49	5662	49	1.10 (0.74-1.64)
Male	3180	20	3180	27	0.81 (0.45-1.45)
Race					
White	7653	60	7653	71	0.92 (0.65-1.30)
Black or African American	610	10	610	10	3.74 (0.74-18.84)
Asian	189	10	189	0	
BMI					
<30	2666	20	2666	24	0.93 (0.51-1.68)
≥30	1936	10	1936	10	0.87 (0.34-2.21)

ILD: Interstitial lung disease.

If the patient's count is 1-10, the results indicate a count of 10.



Figure 3 Forest plot of subgroup analysis

Sensitivity Analysis: Sensitivity analysis was conducted to assess the impact of potential confounders such as body mass index (BMI) and prior SARS-CoV-2 vaccination status on the development of interstitial lung disease (ILD). The analysis confirmed that these factors did not significantly influence the risk of ILD development. Detailed results from this analysis can be found in Table 2, which presents the risk of outcomes in patients exposed to nirmatrelvir-ritonavir compared to Molnupiravir, and the subgroup analyses, including the impact of vaccination status, are depicted in Figure 3 (Forest plot of subgroup analysis).

Discussion

Our study explored the risk of interstitial lung disease (ILD) in COVID-19 patients with autoimmune diseases treated with either nirmatrelvir-ritonavir or Molnupiravir. Consistent with prior research indicating no significant increase in adverse respiratory outcomes in the general population treated with these antivirals(18), our findings reveal a similar non-significant trend in autoimmune populations. Notably, the lack of increased ILD risk across different antiviral treatments suggests that both nirmatrelvir-ritonavir and Molnupiravir maintain similar safety profiles regarding ILD in individuals with autoimmune diseases.

While existing studies have focused on general outcomes associated with these antivirals, few have delved into the specifics of autoimmune conditions like rheumatoid arthritis, particularly its phenotypes such as ILD, which significantly impacts COVID-19 severity(7-15). For example, the recent multicenter cohort study highlighted an increased severity in COVID-19 outcomes among rheumatoid arthritis patients, especially those with ILD, indicating a potentially heightened risk associated with such underlying conditions(19). Our study supports this by demonstrating no additional ILD risk from the antivirals themselves, reinforcing the importance of managing underlying autoimmune pathology rather than focusing solely on the specific antiviral used.

The mechanisms underlying these observations may involve the antivirals' effect on viral replication and the consequent modulation of inflammatory processes that could exacerbate ILD(20-22). These drugs, by inhibiting viral replication, might reduce the overall inflammatory burden, which could be particularly beneficial in patients with pre-existing inflammatory conditions like autoimmune diseases. The similar safety profiles we observed suggest that neither drug significantly alters the disease pathway to a clinically meaningful extent, which is crucial for clinical decision-making in treating COVID-19 among patients with complex autoimmune diseases.

This study stands out due to its robust design, utilizing a large, well-characterized cohort with comprehensive data allowing for detailed subgroup analyses and adjustments for multiple confounders. However, it also faces limitations inherent to its observational nature, such as potential residual confounding and the inability to establish causality. Despite these limitations, the study provides valuable insights into the safety of these treatments in a high-risk population. The use of propensity score matching helped mitigate potential biases, ensuring a more accurate comparison between the two antiviral treatments.

Moreover, the wide confidence intervals in some subgroup analyses, particularly among Black or African American patients, suggest limited statistical power due to a small number of ILD events in these populations. This may hinder the generalizability of our findings to certain demographic groups. Lastly, as this was a retrospective study, we could not account for potential changes in treatment protocols or the emergence of new SARS-CoV-2 variants during the study period, both of which could impact the safety and efficacy profiles of nirmatrelvir-ritonavir and Molnupiravir. Future prospective studies are needed to validate our findings in the context of evolving viral dynamics and treatment landscapes.

Looking ahead, further research should aim to assess the long-term effects of COVID-19 treatments on respiratory outcomes in autoimmune diseases and explore the differential impacts of various autoimmune phenotypes on treatment responses. Specifically, longitudinal studies assessing the interaction between antiviral treatments and immunosuppressive therapies commonly used in autoimmune disease management could provide deeper insights into optimizing treatment protocols. Investigating the interplay between antiviral treatments and specific immunosuppressive therapies commonly used in autoimmune disease management could provide deeper insights into optimizing treatment protocols. Clinically, our results support the continued use of both nirmatrelvir-ritonavir and Molnupiravir in treating COVID-19 in patients with autoimmune diseases, reassuring healthcare providers about the manageable risk profile of these treatments concerning ILD development. Additionally, these findings may inform future guidelines and policy decisions, promoting safer and more effective treatment strategies for this vulnerable patient group.

Conclusion

This retrospective cohort study found no significant difference in the risk of interstitial lung disease (ILD) between COVID-19 patients with autoimmune diseases treated with Paxlovid or Molnupiravir. Both medications appear safe in this population. While the study's design strengthens these findings, limitations such as residual confounding remain. Future research should explore long-term respiratory outcomes to further guide clinical decisions.

reference

1. Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med. 2022;386(15):1397-408.
2. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med. 2022;386(6):509-20.
3. Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19. N Engl J Med. 2021;385(23):e81.
4. Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, et al. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. N Engl J Med. 2022;386(4):305-15.
5. Deepak P, Kim W, Paley MA, Yang M, Carvidi AB, Demissie EG, et al. Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 : A Prospective Cohort Study. Ann Intern Med. 2021;174(11):1572-85.
6. Furer V, Eviatar T, Zisman D, Peleg H, Paran D, Levartovsky D, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis. 2021;80(10):1330-8.

7. Figueroa-Parra G, Aguirre-Garcia GM, Gamboa-Alonso CM, Camacho-Ortiz A, Galarza-Delgado DA. Are my patients with rheumatic diseases at higher risk of COVID-19? Ann Rheum Dis. 2020;79(6):839-40.
8. Strangfeld A, Schäfer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021;80(7):930-42.
9. Raiker R, DeYoung C, Pakhchanian H, Ahmed S, Kavadichanda C, Gupta L, Kardeş S. Outcomes of COVID-19 in patients with rheumatoid arthritis: A multicenter research network study in the United States. Semin Arthritis Rheum. 2021;51(5):1057-66.
10. Faye AS, Lee KE, Laszkowska M, Kim J, Blackett JW, McKenney AS, et al. Risk of Adverse Outcomes in Hospitalized Patients With Autoimmune Disease and COVID-19: A Matched Cohort Study From New York City. J Rheumatol. 2021;48(3):454-62.
11. Pablos JL, Galindo M, Carmona L, Lledó A, Retuerto M, Blanco R, et al. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. Ann Rheum Dis. 2020;79(12):1544-9.
12. Kroon FPB, Najm A, Alunno A, Schoones JW, Landewé RBM, Machado PM, Navarro-Compán V. Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations. Ann Rheum Dis. 2022;81(3):422-32.
13. England BR, Roul P, Yang Y, Kalil AC, Michaud K, Thiele GM, et al. Risk of COVID-19 in Rheumatoid Arthritis: A National Veterans Affairs Matched Cohort Study in At-Risk Individuals. Arthritis Rheumatol. 2021;73(12):2179-88.
14. Bower H, Frisell T, di Giuseppe D, Delcoigne B, Ahlenius GM, Baecklund E, et al. Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision. RMD Open. 2021;7(3).
15. Wang Y, D'Silva KM, Jorge AM, Li X, Lyv H, Wei J, et al. Increased Risk of COVID-19 in Patients With Rheumatoid Arthritis: A General Population-Based Cohort Study. Arthritis Care Res (Hoboken). 2022;74(5):741-7.
16. Wang W, Wang Y-H, Huang C-H, Hsieh T-H, Ibarburu GH, Wei JC-C. Paxlovid use is associated with lower risk of cardiovascular diseases in COVID-19 patients with autoimmune rheumatic diseases: a retrospective cohort study. BMC Medicine. 2024;22(1):117.
17. Wang L, Berger NA, Davis PB, Kaelber DC, Volkow ND, Xu R. COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022. medRxiv. 2022:2022.06.21.22276724.
18. Li J, Liu H-H, Yin X-D, Li C-C, Wang J. COVID-19 illness and autoimmune diseases: recent insights. Inflammation Research. 2021;70(4):407-28.
19. Figueroa-Parra G, Gilbert EL, Valenzuela-Almada MO, Vallejo S, Neville MR, Patel NJ, et al. Risk of severe COVID-19 outcomes associated with rheumatoid arthritis and phenotypic subgroups: a retrospective, comparative, multicentre cohort study. Lancet Rheumatol. 2022;4(11):e765-e74.
20. Mariniello DF, Allocca V, D'Agnano V, Villaro R, Lanata L, Bagnasco M, et al. Strategies Tackling Viral Replication and Inflammatory Pathways as Early Pharmacological Treatment for SARS-CoV-2 Infection: Any Potential Role for Ketoprofen Lysine Salt? Molecules. 2022;27(24):8919.
21. Chathuranga K, Weerawardhana A, Dodantenna N, Lee JS. Regulation of antiviral innate immune signaling and viral evasion following viral genome sensing. Exp Mol Med. 2021;53(11):1647-68.
22. Chaturvedi S, Vasen G, Pablo M, Chen X, Beutler N, Kumar A, et al. Identification of a therapeutic interfering particle-A single-dose SARS-CoV-2 antiviral intervention with a high barrier to resistance. Cell. 2021;184(25):6022-36 e18.